DEVELOPMENT AND EVALUATION OF NOVEL ESTIMATION TECHNIQUES FOR IN VITRO DISSOLUTION STUDY AND VALIDATION PROTOCOL FOR ESCITALOPRAM AS ANTIDEPRESSANT DRUG AND THEIR FORMULATION

  • SHRIRAM H. BAIRAGI Research Scholar, Carrier Point University, Kota, Rajasthan
  • R. S. GHOSH Department of Pharmacy, Carrier Point University, Kota, Rajasthan

Abstract

Objective: To develop and validate the RP-HPLC method and in vitro dissolution study for escitalopram as antidepressant drug and their formulation.


Methods: The chromatographic separation was done by using a C-18, 150 mm column and a mobile phase consisting of phosphate buffer (40%) and acetonitrile HPLC grade (60%). Detection was carried out at 211 nm with a flow rate of 1 ml/min with an injection of 20 μl. The method was validated with different parameters such as linearity, precision, accuracy, robustness, and limit of detection (LOD), the limit of quantification (LOQ) according to ICH guidelines.


Results: The linear calibration curve was obtained in the concentration range of 0-50 μg/ml and gave an average correlation factor 0.992. The retention time was observed at 2.96 min. The Minimum concentration level at which the analyte can be reliably detected (LOD) and quantified (LOQ) were found to be 0.03 and 0.09 µg/ml, respectively. The relative standard deviation of intra and the inter-day assay was found to be less than 2. The dissolution studies show moderate dissolution (23.4%) after 45 min, but it reaches a plateau after approximately 25 min.


Conclusion: This method was found to be simple, rapid and economic with less run time. The validated parameters manifest the method is reliable, linear, accurate and precise as well as robust with minor variations in chromatographic parameters. Therefore, the developed method can be applied for both routine analysis and quality control assay and it could be a very powerful tool to investigate the stability of escitalopram.

Keywords: Escitalopram, RP-HPLC, Dissolution studies, Anti-depressant activity

Downloads

Download data is not yet available.

References

1. Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 2014;10:121-8.
2. Sanchez C, Reines E, Montgomery S. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 2014;29:185-96.
3. Chusena N, Devala R, Pasupuleti U. Development and validation of an RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam in bulk and its pharmaceutical formulations. Int Curr Pharm J 2012;1:193-8.
4. Tapobana S, Dey S, Samal H, Bharat D, Mohanty D, Bhar K, et al. RP-¬HPLC method for the estimation of escitalopram in bulk and in dosage forms. Int J Chem Res 2011;2:11-5.
5. Subash P, Anbazhagan S, Rishop R, Valarmathy S, Winkumar G, Suriya R, et al., RP–HPLC method development and validation for the determination of escitalopram oxalate and clonazepam in tablet dosage form. Int J Res Pharm Pharm Sci 2018;3:35-44.
6. Kakde R, Satone D, Gadapayale K, Kakde M. Stability-indicating RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam. J Chromatogr Sci 2013;51:490-5.
7. Nekkala K, Shanmukha J, Ramachandran D, Ramanaiah G, Srinivas G. Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of escitalopram oxalate and etizolam in bulk and its pharmaceutical formulations. Int J Bioassays 2014;3:3456?63.
8. Bindusar K. Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of escitalopram oxalate and clonazepam in bulk and its pharmaceutical formulations. J Drug Delivery Ther 2019;9:265-74.
9. Mondal P, Santhosh B, Satla S, Raparla R. A new validated simultaneous RP-HPLC method for estimation of escitalopram oxalate and etizolam in bulk and table dosage form. Der Pharm Chem 2013;5:26-32.
10. Damor S, Patel D. Stability-indicating chromatographic method development and validation for the simultaneous estimation of escitalopram oxalate and flupentixol in its pharmaceutical dosage form by HPLC. World J Pharm Res 2017;6:549-66.
11. Krishna V, Gouthami B, Meyyanathan S, Gowramma B, Elango K, Suresh B, et al., In vitro in vivo pharmacokinetic interaction study of escitalopram oxalate when co-administered with caffeine/caffeinated beverages. Open Conference Proceedings J 2013;4:66-71.
12. Bhimanadhuni C, Garikapati D, Usha P. Development and validation of an RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam in bulk and its pharmaceutical formulations. Int Curr Pharmaceutical J 2012;5:193–8.
13. Kalia B, Baghel U. Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of escitalopram oxalate and clonazepam in bulk and its pharmaceutical formulations. J Drug Delivery Ther 2019;15:265–74.
14. Mahadik M, Dhaneshwar S, Kulkarni M. Application of stability-indicating HPTLC method for the quantitative determination of escitalopram oxalate in pharmaceutical dosage form. Eurasian J Anal Chem 2007;2:101-17.
15. ICH, Q2A validation of analytical procedure: international methodology conference on harmonization, Geneva; 1994.
16. ICH, Q2B Validation of analytical procedure: international methodology conference on harmonization, Geneva; 1996.
17. ICH Guidance on Analytical Method Validation. In: Proceedings of the International Convention on Quality for the Pharmaceutical Industry, Toronto, Canada; 2002.
18. Patel S, Maheshwari D. Development and validation of UV spectrometric and HPLC method for estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form. Asian J Pharm Technol Innovation 2016;4:59-70.
Statistics
87 Views | 76 Downloads
Citatons
How to Cite
BAIRAGI, S. H., and R. S. GHOSH. “DEVELOPMENT AND EVALUATION OF NOVEL ESTIMATION TECHNIQUES FOR IN VITRO DISSOLUTION STUDY AND VALIDATION PROTOCOL FOR ESCITALOPRAM AS ANTIDEPRESSANT DRUG AND THEIR FORMULATION”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 8, June 2020, pp. 55-61, doi:10.22159/ijpps.2020v12i8.37964.
Section
Original Article(s)